Sepsis, a clinical systemic inflammatory response syndrome occurring in patients following infection or injury, remains the leading cause of death in intensive care units worldwide, including the United States. Emerging evidence indicates that immunometabolism may play an important role in the pathogenesis of sepsis through its ability to regulate the expression and release of cytokines. In particular, we recently provided the first direct evidence that PKM2-mediated aerobic glycolysis promotes the release of HMGB1, a late mediator of lethal systemic inflammation with a wider therapeutic time window for clinical intervention. These exciting findings raise several important questions regarding the previously unknown role of PKM2 in the pathogenesis of sepsis, as well as the novel mechanisms underlying the regulation of PKM2 expression and HMGB1 release. We hypothesize that PKM2-mediated immunometabolism is an emerging hallmark of sepsis that contributes to cytokine (e.g., HMGB1) release and the subsequent systemic inflammatory response. We propose the following specific aims:
Aim 1. Define the mechanism underlying the regulation of PKM2 expression and activity in both immune and non-immune cells during sepsis. We will test the hypothesis that AMPK is a negative regulator of PKM2 expression and activity, and therefore suppresses aerobic glycolysis and HMGB1 release in activated macrophages, monocytes, and endothelial cells in vitro and in vivo.
Aim 2. Define the mechanism underlying the regulation of HMGB1 release by aerobic glycolysis in both immune and non-immune cells during sepsis. We will test the hypothesis that metabolites production (e.g., lactate) from PKM2-mediated aerobic glycolysis can inhibit the activity of histone deacetylases including SIRT1, which in turn enables HMGB1 hyperacetylation and subsequent release in activated macrophages, monocytes, and endothelial cells in vitro and in vivo.
Aim 3. Determine the efficacy of PKM2 inhibition in protecting against sepsis in two experimental animal models. We will test the hypothesis that mice with PKM2 ablation in myeloid cells are protected from lethal endotoxemia or cecal ligation and puncture-induced polymicrobial sepsis through altering lactate accumulation, HMGB1 release, inflammatory response, and organ dysfunction. The completion of these exciting studies will further improve our understanding of the emerging role of immunometabolism in inflammation and the mechanisms of HMGB1 release and guide future development of therapeutic strategies to treat sepsis and other lethal inflammatory diseases.

Public Health Relevance

Despite recent advances in antibiotic therapy and intensive care, severe sepsis and septic shock remain the leading causes of death in intensive care units worldwide, including the United States. We postulate that the dysfunction of PKM2-mediated immunometabolism is an emerging hallmark of sepsis that can regulate HMGB1 release and the subsequent systemic inflammatory response. Our proposal will provide new insights into our understanding of the pathophysiology of sepsis and may lead to new therapeutic strategies to treat this lethal inflammatory disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM115366-01
Application #
8937151
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Dunsmore, Sarah
Project Start
2015-07-15
Project End
2019-05-31
Budget Start
2015-07-15
Budget End
2016-05-31
Support Year
1
Fiscal Year
2015
Total Cost
$304,150
Indirect Cost
$106,650
Name
University of Pittsburgh
Department
Surgery
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kang, Rui; Zhu, Shan; Zeh, Herbert et al. (2018) The STING-STAT6 pathway drives Cas9-induced host response in human monocytes. Biochem Biophys Res Commun 506:278-283
Liao, Yuning; Xia, Xiaohong; Liu, Ningning et al. (2018) Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene 37:1896-1910
Li, Changfeng; Zhang, Ying; Cheng, Xing et al. (2018) PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Dev Cell 46:441-455.e8
Deng, Wenjun; Zhu, Shan; Zeng, Ling et al. (2018) The Circadian Clock Controls Immune Checkpoint Pathway in Sepsis. Cell Rep 24:366-378
Kang, Rui; Kroemer, Guido; Tang, Daolin (2018) The tumor suppressor protein p53 and the ferroptosis network. Free Radic Biol Med :
Kang, Rui; Zeng, Ling; Zhu, Shan et al. (2018) Lipid Peroxidation Drives Gasdermin D-Mediated Pyroptosis in Lethal Polymicrobial Sepsis. Cell Host Microbe 24:97-108.e4
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Song, Xinxin; Zhu, Shan; Chen, Pan et al. (2018) AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity. Curr Biol 28:2388-2399.e5
Wang, Ding; Xie, Nan; Gao, Wanli et al. (2018) The ferroptosis inducer erastin promotes proliferation and differentiation in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 503:1689-1695
Song, Xinxin; Zhu, Shan; Xie, Yangchun et al. (2018) JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology 154:1480-1493

Showing the most recent 10 out of 32 publications